Richard Nolan Townsend - Aug 12, 2024 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Role
Chief Executive Officer, Director
Signature
/s/ Youjin Choi, Attorney-in-Fact
Stock symbol
LXEO
Transactions as of
Aug 12, 2024
Transactions value $
-$45,985
Form type
4
Date filed
8/13/2024, 06:34 PM
Previous filing
Jul 12, 2024
Next filing
Sep 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXEO Common Stock Options Exercise $11.7K +5K +4.14% $2.33 126K Aug 12, 2024 Direct F1
transaction LXEO Common Stock Sale -$57.6K -5K -3.98% $11.53 121K Aug 12, 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LXEO Stock Option (right to buy) Options Exercise $0 -5K -3.61% $0.00 134K Aug 12, 2024 Common Stock 5K $2.33 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The exercises and sales in this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $11.05 to $11.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 Includes 43,750 restricted stock units (RSU's). Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F4 25% of the shares underlying the option vested on November 21, 2021, and 1/48th of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.